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The present case report describes a case of recurrent and advanced urachal carcinoma including 
neuroendocrine features with iliac bone metastasis after partial cystectomy and adjuvant chemother-
apy consisting of irinotecan and cisplatin in a 32-year-old man.  He received gemcitabine/cisplatin/
paclitaxel (GCP) combination chemotherapy,  consisting of gemcitabin (1,000mg/m2) on day 1,  8,  cis-
platin (70mg/m2) on day 1,  and paclitaxel (80mg/m2) on day 1 and 8.  After three cycles of chemo-
therapy,  PET-CT showed complete regression of the disease.  So the patient underwent total cystoure-
threctomy,  and histological examination showed an almost complete pathological response.  External 
beam radiation therapy was also given to the ileac bone metastasis regions.  However,  PET-CT taken 
17 months after the external beam radiation showed multiple lung metastases.  He received GCP che-
motherapy again,  which resulted in a complete response again after three cycles of chemotherapy.  
This is the ﬁrst report on GCP chemotherapy used not only as a salvage chemotherapy but also as a 
rechallenge regimen for metastatic urachal cancer including a neuroendocrine component.
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U rachal cancer is a rare malignancy,  and the standard treatment is en bloc resection.  The 
prognosis of recurrent and metastatic urachal cancer 
is extremely poor,  because there is no established 
chemotherapy regimen.  The choice of regimen is 
largely based on case reports.  The present report is 
the ﬁrst to describe the use of gemcitabine/cisplatin/
paclitaxel (GCP) combination chemotherapy for recur-
rent and metastasis urachal cancer including a neuro-
endocrine component.
Case Report
　 A 32-year-old man presented to a previous hospital 
complaining of gross hematuria.  Cystoscopy,  magnetic 
resonance imaging (MRI) and computed tomography 
(CT) showed a bladder tumor at the dome of the blad-
der.  He was treated with partial cystectomy,  and 
histological examination showed adenocarcinoma, which 
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spread from the urachus and extended to the bladder 
muscle and peritoneum.  He was diagnosed with ura-
chal adenocarcinoma with peritoneal invasion,  then 
referred to Okayama University Hospital for addi-
tional treatment.  A second look at the pathologic 
samples by a pathologist at our university revealed a 
mixed type of adenocarcinoma and small cell carcinoma 
using hematoxylin and eosin staining (Fig.  1A),  and 
immunohistological examination revealed a dominant 
neuroendocrine by CD56 (Fig.  1B),  synaptophysin 
(Fig.  1C) and chromogranin-A staining (Fig.  1D).  
Three cycles of irinotecan (CPT-11,  70mg/m2) on 
day 1,  15 and cisplatin (CDDP,  80mg/m2) on day 1 
chemotherapy were introduced according to the che-
motherapy regimen for neuroendocrine gastric cancer.  
One year after the chemotherapy,  cystoscopy showed 
tumor recurrence at the bladder dome (Fig.  2),  MRI 
showed extravesical invasion and ileac bone metasta-
sis,  and positron emission tomography (PET-CT) also 
showed high uptake of 18F-FDG at the bladder dome 
and ileac bone (Fig.  3).  Then,  a GCP chemotherapy 
regimen was administered every 4 weeks and 3 cycles.  
This regimen consisted of GEM (1,000mg/m2) on day 
1,  8,  CDDP (70mg/m2) on day 1,  and paclitaxel 
(PTX,  80mg/m2) on day 1,  8.  After the 3 cycles of 
GCP chemotherapy,  PET-CT showed complete 
regression of the bladder and ileac bone disease.  Then 
total cystourethrectomy and pelvic lymphadectomy 
were performed.  Histological examination showed a 
small volume (less than 1 ) of residual viable cells,  a 
major volume of necrosis and ﬁbrosis in the bladder 
region and no lymph node metastasis.  Furthermore,  
external beam radiation therapy (a total of 50 Gy in 
25 fractions) was also given to the ileac bone metasta-
sis regions at 1 month after the operation.  However,  
17 months after the external beam radiation,  PET-CT 
showed multiple lung metastases (Fig.  4A).  Three 
cycles of GCP chemotherapy were again administered,  
and PET-CT showed that the lung metastasis had 
disappeared after chemotherapy (Fig.  4B).  The 
patient remained free of disease at 3 months after 
treatment.  Although grade 3 bone marrow suppres-
sion occurred during GCP chemotherapy,  the patient 
completed treatment without interruption or reduction 
of the chemotherapy dose.




Fig. 1　 The hematoxylin and eosin histology (A) suggested adenocarcinoma and small cell carcinoma. Immunohistological examination 
by CD56 (B),  synaptophysin (C),  and chromogranin-A staining (D) suggested dominantly proliferated neuroendocrine components around 
the adenocarcinoma.
Discussion
　 Urachal carcinoma is a rare malignancy of the blad-
der which accounts for less than 1  of all bladder 
cancers,  and its histological feature is usually adeno-
carcinoma,  although other subtypes have been 
described [1].  The prognosis of metastatic urachal 
cancer is extremely poor.  Ashley et al.  reviewed the 
clinicopathological features and cancer-speciﬁc sur-
vival of 66 urachal carcinoma patients at their institu-
tion and reported that 92  with metastatic urachal 
carcinoma died of their disease,  the median time from 
the diagnosis of metastasis to death was just over 1 
year,  and no diﬀerence in the time from metastasis to 
death was noted between patients who did and did not 
receive chemotherapy [2].
　 Unlike other cancers,  there is currently no stan-
dard chemotherapy regimen for the treatment of ura-
chal cancers.  According to the National Compre- 
hensive Cancer Network (NCCN) guidelines (version 
2; 2015),  cystectomy or partial cystectomy with en 
block resection of the urachal ligament is recom-
mended for local disease,  and clinical trial or combi-
nation chemotherapy may be considered for selected 
advanced-disease patients.  Histologically,  urachal 
adenocarcinoma has been found to be similar to gastric 
and colon adenocarcinoma,  and in some studies CPT-
11-based chemotherapy [3] and FOLFOX-based 
chemotherapy [4] have been reported to be eﬃcacious 
for treating metastatic urachal adenocarcinoma.  On 
the other hand,  for small cell carcinoma or neuroen-
docrine component of bladder cancer,  neoadjuvant 
chemotherapy and local treatment including cystec-
tomy are recommended,  and the suggested primary 
chemotherapy regimens are similar to those recom-
mended for small cell lung cancer in the NCCN 
guidelines.
　 The treatment course of our case is shown in Table 1.  
The pathological examination of the ﬁrst partial cys-
tectomy revealed a dominant neuroendocrine compo-
nent (not adenocarcinoma) and peritoneal invasion of 
cancer cells.  This neuroendocrine component in ura-
chal cancer is very rare and made it diﬃcult to decide 
on whether to administer an adjuvant treatment.  
Although there is no evidence the eﬃcacy of adjuvant 
chemotherapy,  we focused on the pathological ﬁnding 
of peritoneal invasion and decided to introduce adju-
vant chemotherapy.  Some reports have shown the 
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Fig. 4　 PET-CT of the lung metastasis.  (A) High uptake of 18F-
FDG in rt lung (SUV max of 17. 67) before GCP chemotherapy.  (B) 
The high uptake disappeared in the lung.
Fig. 3　 PET-CT showed a solitary mass at the iliac bone and 
extravesica (SUV max of 18.62).
eﬃcacy of CPT-11 plus CDDP chemotherapy for small 
cell lung cancer [5] and gastric small cell carcinoma 
[6]; therefore,  we undertook a gastric small cell 
carcinoma regimen in our hospital.  However,  local 
recurrence and distant metastasis were observed at 
one year after the CPT-11 plus CDDP chemotherapy.  
　 At this time,  salvage chemotherapy was discussed.  
We focused on GEM/CDDP chemotherapy,  which 
has been reported to treat recurrent and metastatic 
urachal adenocarcinoma with some success [7].  
Recently,  the combination of GEM/CDDP has become 
a new standard treatment in metastatic urothelial 
bladder cancer based on randomized trials showing 
similar survival but a more favorable toxicity proﬁle 
[8].  Moreover,  Bellmunt et al.  reported a higher 
response rate and a better survival beneﬁt after 
GEM/CDDP plus PTX chemotherapy compared to 
GEM/CDDP chemotherapy [9].  We have also 
reported a survival beneﬁt of salvage surgery for 
metastatic urothelial cancer patients after GEM/
CDDP or GEM/CDDP plus PTX chemotherapy 
[10].  That is why we introduced GCP chemotherapy 
for recurrence and metastasis after the CPT-11 plus 
CDDP chemotherapy.  PET-CT showed a complete 
response,  and a pathological examination at total 
cystourethrectomy also revealed a nearly complete 
response.  Moreover,  CT showed complete deletion of 
the lung metastasis after a rechallenge with GCP 
chemotherapy.  These results were much better than 
we expected.  This is the ﬁrst report of the use of 
GCP chemotherapy not only as a salvage chemother-
apy but also as a rechallenge regimen for metastatic 
urachal cancer including a neuroendocrine component.  
In the absence of a standard chemotherapeutic regi-
men,  GCP chemotherapy might be considered for the 
treatment of advanced urachal cancer including a 
neuroendocrine component.
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Table 1　 Treatment course of this case report
Duration from Evaluation before therapy
Therapy
Evaluation after therapy
previous therapy Cystoscopy / Imaging Pathology Imaging




CPT-11 / CDDP 3C
12 months Bladder recurrence   (Fig. 2)
Ileac bone metastasis(Fig. 3)
GCP 3C CR
Total cystourethrectomy Almost CR
Pelvic lymphadectomy
RT for ileac bone 
metastasis
17 months Lung meta.            (Fig. 4A)
GCP 3C CR 
(Fig. 4B)
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